Eli Lilly and Company (NYSE: LLY) partners with Superluminal Medicines in a $1.3 billion deal to use AI for drug discovery in obesity and cardiometabolic diseases. The company aims to solidify its position in the $150 billion obesity treatment market by developing next-generation drugs and forming strategic partnerships.

Eli Lilly (LLY) secures exclusive rights to develop and commercialize drug candidates discovered through Superluminal’s AI platform targeting G-protein-coupled receptors. These proteins play a role in various physiological processes like metabolism and immune responses. The company is focused on innovation in the pharmaceutical industry.

Eli Lilly and Company (NYSE: LLY) is a multinational pharmaceutical company known for its innovative medicines. The partnership with Superluminal Medicines highlights its commitment to advancing drug discovery through AI technology. The company is positioning itself as a leader in the obesity treatment market through strategic collaborations and acquisitions.

Read more at Yahoo Finance: Eli Lilly (LLY) Partners with Superluminal for AI Drug Discovery